

Kisunla™ (donanemab-azbt) (Intravenous)

Document Number: IC-0763

Last Review Date: 11/04/2025

Date of Origin: 08/01/2024

Dates Reviewed: 08/2024, 11/2024, 08/2025, 11/2025

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 6 months.
- Renewal: Prior authorization validity may be renewed annually thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- Doses are administered every four weeks as follows:
 - Infusion 1: 175 billable units
 - Infusion 2: 350 billable units
 - Infusion 3: 525 billable units
 - Infusion 4 and beyond: 700 billable units every four weeks thereafter.

III. Initial Approval Criteria ^{1,5,6,9,11}

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Physician has assessed baseline disease severity utilizing at least ONE objective measure/tool (i.e., Mini-Mental Status Exam [MMSE], Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog-13/14], Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment version [ADCS-ADL-MCI], Clinical Dementia Rating-Sum of Boxes [CDR-SB], Montreal Cognitive Assessment (MoCA), etc.); **AND**
- Patient does not have any of the following risk factors for intracerebral hemorrhage: findings suggestive of cerebral amyloid angiopathy (prior cerebral hemorrhage > 1 cm in greatest diameter, > 4 microhemorrhages, superficial siderosis, vasogenic edema); **AND**
- Patients receiving antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) prior to starting treatment with Kisunla have been on a stable dose for at least 4 weeks; **AND**
 - Patient has been tested prior to treatment to assess apolipoprotein E ε4 (ApoE ε4) status (e.g., homozygote, heterozygote, or noncarrier) and the prescriber has informed the patient that those who are homozygotes have a higher incidence of developing Amyloid-Related Imaging Abnormalities (ARIA); **OR**
 - Genotype testing has not been performed and the prescriber has informed the patient that it cannot be determined if they are ApoE ε4 homozygotes and, therefore, if they are at higher risk for developing ARIA; **AND**

Universal Criteria ¹

- Must be prescribed by, or in consultation with, a specialist in neurology or gerontology; **AND**
- Patient has received a baseline brain magnetic resonance imaging (MRI) prior to initiating treatment and periodically throughout therapy (*see prescribing information for schedule of MRI scans*); **AND**
- Will not be used concurrently with other anti-amyloid immunotherapies (i.e., lecanemab IV/SQ, etc.); **AND**

Alzheimer's Disease (AD) † ^{1,2,5,6,11-13}

- Patient has a diagnosis of mild cognitive impairment (MCI) due to AD or has mild Alzheimer's dementia (there is insufficient evidence in moderate or severe AD) **AND** both of the following:
 - Positron Emission Tomography (PET) scan positive for amyloid beta plaque or cerebrospinal fluid (CSF) assessment positive for hybrid ratios of A β 42/40, CSF p-tau 181/A β 42, or CSF t-tau/A β 42; **AND**
 - One of the following*:
 - Clinical Dementia Rating (CDR)-Global Score of 0.5-1.0 with Memory Box Score of at least 0.5; **OR**
 - Mini-Mental Status Exam (MMSE) score between 20-28, inclusive; **OR**
 - Montreal Cognitive Assessment (MoCA) score 18-25, inclusive; **AND**
- Other conditions mimicking, but of non-Alzheimer's Dementia etiology, have been ruled out (e.g., vascular dementia, dementia with Lewy bodies [DLB], frontotemporal dementia [FTD], normal pressure hydrocephalus, etc.)

** Note: The aforementioned cognitive tests are typically the most commonly used but do NOT represent an exhaustive list. Use of alternative cognitive assessment tests not listed will be reviewed on a case-by-case basis.*

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓞ Orphan Drug

IV. Renewal Criteria ^{1,5,6}

Prior authorization validity may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: amyloid related imaging abnormalities-edema (ARIA-E) and -hemosiderin deposition (ARIA-H), intracerebral hemorrhage, hypersensitivity reactions including anaphylaxis and angioedema, infusion-related reactions, etc.; **AND**
- Patient has responded to therapy as evidenced by disease stability or slowing of progression in cognitive and/or functional impairment in one or more of the following (not all-inclusive): ADAS-Cog 13/14; ADCS-ADL-MCI; MMSE; CDR-SB, MoCA, etc.; **AND**

- Patient will discontinue treatment when reduction of amyloid plaques are reduced to minimal levels on amyloid PET imaging, defined as either of the following:
 - Level is <11 Centiloids on a single PET scan; **OR**
 - Level is 11 to <25 Centiloids on two consecutive PET scans; **AND**
- Patient has not progressed to moderate or severe AD; **AND**
- Patient has received a pre- 2nd, 3rd, 4th, AND 7th infusion MRI for monitoring of Amyloid Related Imaging Abnormalities-edema (ARIA-E) and Amyloid Related Imaging Abnormalities-hemosiderin (ARIA-H) microhemorrhages; **AND**

ARIA-E §

- Patient is asymptomatic or mildly symptomatic* with mild radiographic severity** on MRI; **OR**
- Patient is asymptomatic or mildly symptomatic* with moderate to severe radiographic severity** on MRI AND administration will be suspended until MRI demonstrates radiographic resolution and symptoms, if present, resolve; **OR**
- Patient has moderate to severe symptoms* with mild to severe radiographic severity** on MRI AND administration will be suspended until MRI demonstrates radiographic resolution and symptoms, if present, resolve

ARIA-H §

- Patient is asymptomatic with mild radiographic severity** on MRI; **OR**
- Patient is asymptomatic with moderate radiographic severity** on MRI AND administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; **OR**
- Patient is symptomatic with mild to moderate radiographic severity** on MRI AND administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; **OR**
- Patient has severe radiographic severity** on MRI AND administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve

§ *Clinical judgment will be used in considering whether to continue treatment or permanently discontinue. In patients who develop intracerebral hemorrhage greater than 1 cm in diameter during treatment with Kisunla, suspend dosing until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification.*

Clinical Symptom Severity *		
Mild	Moderate	Severe
Discomfort noticed, but no disruption of normal daily activity	Discomfort sufficient to reduce or affect normal daily activity	Incapacitating, with inability to work or to perform normal daily activity

ARIA-E Symptom Severity ¹	ARIA-E Radiographic Severity**		
	Mild	Moderate	Severe

Asymptomatic	May continue dosing at current dose and schedule	Suspend until MRI demonstrates radiographic resolution and symptoms, if present, resolve; consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification. Resumption of dosing should be guided by clinical judgment.
Mild	May continue dosing based on clinical judgment	
Moderate or Severe	Suspend until MRI demonstrates radiographic resolution and symptoms, if present, resolve; consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification. Resumption of dosing should be guided by clinical judgment.	

ARIA-H Symptom Severity ¹	ARIA-H Radiographic Severity**		
	Mild	Moderate	Severe
Asymptomatic	May continue dosing at current dose and schedule	Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; resumption of dosing should be guided by clinical judgment; consider a follow-up MRI to assess for stabilization 2 to 4 months after initial identification.	Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Use clinical judgment when considering whether to continue treatment or permanently discontinue KISUNLA.
Symptomatic	Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; resumption of dosing should be guided by clinical judgment; consider a follow-up MRI to assess for stabilization 2 to 4 months after initial identification.		

ARIA Type ¹	Radiographic Severity**		
	Mild	Moderate	Severe
ARIA-E	FLAIR hyperintensity confined to sulcus and/or cortex/subcortex white matter in one location < 5 cm	FLAIR hyperintensity 5 to 10 cm in single greatest dimension, or more than 1 site of involvement, each measuring < 10 cm	FLAIR hyperintensity measuring > 10 cm with associated gyral swelling and sulcal effacement. One or more separate/independent sites of involvement may be noted.
ARIA-H microhemorrhage	≤ 4 new incident microhemorrhages	5 to 9 new incident microhemorrhages	10 or more new incident microhemorrhages
ARIA-H superficial siderosis	1 new focal area of superficial siderosis	2 new focal areas of superficial siderosis	> 2 new focal areas of superficial siderosis

V. Dosage/Administration ¹

Indication	Dose
Alzheimer's Disease (AD)	Administer Kisunla every 4 weeks as an intravenous infusion over approximately 30 minutes with the recommended dosage and dosing schedule provided in the table below.

	Intravenous Infusion (every 4 weeks)	Kisunla Dosage (administered over approximately 30 minutes)
	Infusion 1	350 mg
	Infusion 2	700 mg
	Infusion 3	1,050 mg
	Infusion 4 and beyond	1,400 mg

– Obtain a recent baseline brain magnetic resonance imaging (MRI) prior to initiating treatment with KISUNLA. Obtain an MRI prior to the 2nd, 3rd, 4th, and 7th infusions. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated.

– If an infusion is missed, resume administration every 4 weeks at the same dose as soon as possible.

VI. Billing Code/Availability Information

HCPCS Code:

- J0175 – Injection, donanemab-azbt, 2 mg: 1 billable unit = 2 mg

NDC:

- Kisunla 350 mg/20 mL (17.5 mg/mL) solution in a single-dose vial: 00002-9401-xx

VII. References

1. Kisunla [package insert]. Indianapolis, IN; Eli Lilly, Inc; July 2025. Accessed October 2025.
2. McKhann GM, Knopman DS, Chertklow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):263. Epub 2011 Apr 21.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):280. Epub 2011 Apr 21.
4. Mintun M, Ritchie CW, Solomon P, et al. Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety in TRAILBLAZER-ALZ 2, a Phase 3 Randomized Clinical Trial. *Alzheimer's Dement.*, 19: e082733. <https://doi.org/10.1002/alz.082733>.
5. Salloway S, Lee E, Papka M, Pain A, Oru E, Ferguson M, et al. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease (S26.009). *Neurology.* 2023;100(17 Supplement 2):3126.
6. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *Jama.* 2023.
7. O'Bryant SE, Lacritz LH, Hall J, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center. *Arch Neurol.* 2010 Jun;67(6):746-9. doi: 10.1001/archneurol.2010.115.

8. Skinner J, Carvalho, JO, Potter GG, et al. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. *Brain Imaging Behav.* 2012 Dec;6(4):489-501. doi: 10.1007/s11682-012-9166-3.
9. Lin GA, Whittington MD, Synnott PG, et al. Aducanumab for Alzheimer's Disease: Effectiveness and Value; Final Evidence Report and Meeting Summary. Institute for Clinical and Economic Review, August 5, 2021. <https://icer.org/assessment/alzheimers-disease-2021/>.
10. Lin GA, Whittington MD, Wright A, et al. Beta-Amyloid Antibodies for Early Alzheimer's Disease: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, December 22, 2022. <https://icer.org/assessment/alzheimers-disease-2022/#timeline>.
11. Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's Dement.* 2024; 20: 5143–5169. <https://doi.org/10.1002/alz.13859>.
12. Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J; Alzheimer's Disease Neuroimaging Initiative. Staging Disease Severity Using the Alzheimer's Disease Composite Score (ADCOMS): A Retrospective Data Analysis. *Neurol Ther.* 2022 Mar;11(1):413-434. doi: 10.1007/s40120-022-00326-y. Epub 2022 Jan 31. Erratum in: *Neurol Ther.* 2022 Jun;11(2):915-927. doi: 10.1007/s40120-022-00340-0. PMID: 35099758; PMCID: PMC8857364.
13. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.
14. Wang H, Serap Monkul Nery E, Ardayfio P, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. *Alzheimers Dement.* 2025 Apr;21(4):e70062. doi: 10.1002/alz.70062. PMID: 40172303; PMCID: PMC11963282.

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime's assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	Yes: Consider for PA
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
G30.0	Alzheimer's disease with early onset
G30.1	Alzheimer's disease with late onset
G30.8	Other Alzheimer's disease
G30.9	Alzheimer's disease, unspecified
G31.84	Mild cognitive impairment of uncertain or unknown etiology

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC